SLC5A2 and hydrops fetalis: SGLT2 inhibitors, such as dapagliflozin and empagliflozin, were particularly effective in reducing the risk of heart failure and improving renal outcomes, as evidenced in the DAPA-HF [15] and EXSCEL [14] analyses, where reductions in worsening heart failure, cardiovascular death, and eGFR decline were significant.